(Updated - July 26, 2019 4:16 PM EDT)Sanofi today announced topline results from three Phase 3 trials of ZynquistaTM (sotagliflozin) ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Hot Corp. News Hot FDA News

Lexicon Pharmaceuticals (LXRX) PT Lowered to $3 at CitiJuly 30, 2019 2:50 AM Sanofi (SNY) Reports Q2 Loss of EUR0.07 on Revenues of EUR8.63BJuly 29, 2019 5:58 AM UPDATE: Lexicon Pharma (LXRX) Reports Prelim. Update for Zynquista (Sotagliflozin) Type 2 Diabetes Phase 3 Program; Confirms Sanofi (SNY) to Terminate CollaborationJuly 29, 2019 5:45 AM Sanofi :  Sanofi provides update on ZynquistaTM (sotagliflozin) type 2 diabetes Phase 3 program and collaboration with LexiconJuly 26, 2019 4:05 PM